CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2020; 80(04): 391-398
DOI: 10.1055/a-1111-8775
GebFra Science
Review/Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics

Article in several languages: English | deutsch
Diana Lüftner
1  Charité University Hospital, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany
,
Andreas Schneeweiss
2  National Center for Tumor Diseases, Division Gynecologic Oncology, University Hospital and German Cancer Research Center, Heidelberg, Germany
,
Andreas D. Hartkopf
3  Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
,
Volkmar Müller
4  Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Achim Wöckel
5  Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Wolfgang Janni
6  Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Johannes Ettl
7  Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
,
Erik Belleville
8  ClinSol GmbH & Co KG, Würzburg, Germany
,
Florian Schütz
9  Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
,
Marc Thill
10  Agaplesion Markus Krankenhaus, Frauenklinik, Frankfurt, Germany
,
Jens Huober
6  Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Peter A. Fasching
11  Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Hans-Christian Kolberg
12  Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Patrik Pöschke
11  Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Manfred Welslau
13  Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Friedrich Overkamp
14  OncoConsult Overkamp GmbH, Berlin, Germany
,
Hans Tesch
15  Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany
,
Tanja N. Fehm
16  Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
,
Michael P. Lux
17  Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany
› Author Affiliations
Further Information

Publication History

received 27 January 2020
revised 03 February 2020

accepted 03 February 2020

Publication Date:
21 April 2020 (online)

  

Abstract

For patients with locally advanced or metastatic breast cancer, new and effective therapies such as CDK4/6 inhibitors, PARP inhibitors and a PD-L1 inhibitor have been introduced in recent years. This review presents an update on the available studies with their data. In addition, two innovative anti-HER2 therapies are presented (trastuzumab-deruxtecan and tucatinib) for which the results from new studies have been reported. Molecular tests offer the possibility of defining patient populations or also monitoring courses of therapy. This can help identify patients with specific characteristics in order to provide them with individually targeted therapy within the framework of studies. In a large study, the benefit of such a biomarker study was able to be described for the first time.